News

2017

Flagship Pioneering and its portfolio companies make news because of their transformative approaches to solving global challenges. If you have needs beyond these resources, please contact press@flagshippioneering.com.

company

year

domain

Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric Ulcerative Colitis

Seres Therapeutics 12.04.2017

Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology

Seres Therapeutics 11.14.2017

Seres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic Candidate

Seres Therapeutics 11.07.2017

Seres Therapeutics Reports Positive Topline Results from SER-287 Phase 1b Study in Patients with Ulcerative Colitis

Seres Therapeutics 10.02.2017

Seres Therapeutics Strengthens Board of Directors with Appointment of Willard Dere, M.D., Former Amgen Chief Medical Officer

Seres Therapeutics 07.10.2017

Seres Therapeutics Initiates SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection

Seres Therapeutics 06.12.2017

Seres Therapeutics Announces Completion of Enrollment for SER-287 Phase 1b Study in Patients with Ulcerative Colitis

Seres Therapeutics 06.05.2017

Seres Therapeutics to Initiate New SER-109 Clinical Study

Seres Therapeutics 03.16.2017

Loading